Trevena Future Growth
Future criteria checks 0/6
Trevena's revenue and earnings are forecast to decline at 2.8% and 1.5% per annum respectively while EPS is expected to grow by 20.1% per annum.
Key information
-1.5%
Earnings growth rate
20.1%
EPS growth rate
Biotechs earnings growth | 28.1% |
Revenue growth rate | -2.8% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 09 Aug 2024 |
Recent future growth updates
Recent updates
Trevena Q2 2022 Earnings Preview
Aug 10Trevena slides on $2M preferred stock offering
Jul 29Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely
Jul 08Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?
Mar 19Trevena Offers An Enticing Risk-Reward At These Prices
Dec 14Trevena: Remaining Patient After A Disappointing Q2 Earnings
Aug 17Trevena announces resumption of NIH-run trial for TRV734 in opioid use disorder
Jun 16Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles
May 10Trevena Investor Presentation - Slideshow
May 08Trevena (TRVN) Investor Presentation - Slideshow
Nov 16Trevena: Reaffirming A Buy On OLINVYK DEA Scheduling
Nov 09DEA classifies Trevena's oliceridine, distribution to start in November
Oct 30Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -32 | N/A | N/A | 1 |
12/31/2025 | 9 | -21 | N/A | N/A | 2 |
12/31/2024 | 0 | -26 | N/A | N/A | 1 |
6/30/2024 | 0 | -37 | -32 | -32 | N/A |
3/31/2024 | 3 | -40 | -32 | -32 | N/A |
12/31/2023 | 3 | -40 | -33 | -33 | N/A |
9/30/2023 | 3 | -31 | -38 | -38 | N/A |
6/30/2023 | 3 | -38 | -39 | -39 | N/A |
3/31/2023 | 0 | -45 | -44 | -44 | N/A |
12/31/2022 | 0 | -54 | -52 | -51 | N/A |
9/30/2022 | 0 | -61 | -53 | -53 | N/A |
6/30/2022 | 0 | -59 | -54 | -54 | N/A |
3/31/2022 | 0 | -58 | -54 | -54 | N/A |
12/31/2021 | 1 | -52 | -50 | -50 | N/A |
9/30/2021 | 1 | -50 | -45 | -45 | N/A |
6/30/2021 | 3 | -41 | -36 | -36 | N/A |
3/31/2021 | 3 | -33 | -30 | -30 | N/A |
12/31/2020 | 3 | -29 | -21 | -21 | N/A |
9/30/2020 | 3 | -24 | -21 | -21 | N/A |
6/30/2020 | 0 | -27 | -25 | -25 | N/A |
3/31/2020 | 0 | -25 | -22 | -22 | N/A |
12/31/2019 | 0 | -25 | -24 | -24 | N/A |
9/30/2019 | 0 | -26 | -22 | -23 | N/A |
6/30/2019 | 3 | -22 | -20 | -20 | N/A |
3/31/2019 | 6 | -27 | -23 | -23 | N/A |
12/31/2018 | 6 | -31 | -26 | -25 | N/A |
9/30/2018 | 6 | -38 | -32 | -31 | N/A |
6/30/2018 | 3 | -49 | -41 | -39 | N/A |
3/31/2018 | N/A | -60 | N/A | -52 | N/A |
12/31/2017 | N/A | -72 | N/A | -71 | N/A |
9/30/2017 | N/A | -93 | N/A | -87 | N/A |
6/30/2017 | N/A | -107 | N/A | -100 | N/A |
3/31/2017 | 2 | -106 | N/A | -100 | N/A |
12/31/2016 | 4 | -103 | N/A | -92 | N/A |
9/30/2016 | 6 | -82 | N/A | -76 | N/A |
6/30/2016 | 8 | -63 | N/A | -63 | N/A |
3/31/2016 | 8 | -55 | N/A | -55 | N/A |
12/31/2015 | 6 | -51 | N/A | -40 | N/A |
9/30/2015 | 4 | -48 | N/A | -41 | N/A |
6/30/2015 | 3 | -53 | N/A | -40 | N/A |
3/31/2015 | 1 | -53 | N/A | -40 | N/A |
12/31/2014 | N/A | -50 | N/A | -40 | N/A |
9/30/2014 | N/A | -43 | N/A | -37 | N/A |
6/30/2014 | N/A | -37 | N/A | -33 | N/A |
3/31/2014 | 0 | -30 | N/A | -28 | N/A |
12/31/2013 | 0 | -24 | N/A | -24 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TRVN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TRVN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TRVN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TRVN's revenue is expected to decline over the next 3 years (-2.8% per year).
High Growth Revenue: TRVN's revenue is forecast to decline over the next 3 years (-2.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TRVN's Return on Equity is forecast to be high in 3 years time